Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity

Bibliography

• Lenz W. The susceptible period for thalidomide malformations in man and monkey. Ger Med Mon 1968;13:197-8
   PubMedGoogle Scholar
• Lenz W. Thalidomide embryopathy in Germany, 1959 – 1961. Prog Clin Biol Res 1985;163C:77-83
   PubMedGoogle Scholar
• Hales BF. Thalidomide on the comeback trail. Nat Med 1999;5:489-90
   PubMed Web of Science ®Google Scholar
• Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319-30
   PubMed Web of Science ®Google Scholar
• Stirling D. I.Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1998;17:231-42
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
   PubMed Web of Science ®Google Scholar
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin Hematol 2005;42:S3-8
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R. Thalidomide in multiple myeloma. Expert Opin Pharmacother 2006;7:195-213
   PubMed Web of Science ®Google Scholar
• Kumar S, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol 2005;2:262-70
   PubMedGoogle Scholar
• Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs 2005;14:1411-8
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30
   PubMed Web of Science ®Google Scholar
• Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-79
   PubMed Web of Science ®Google Scholar
• Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8
   PubMed Web of Science ®Google Scholar
• Reist M, Carrupt PA, Francotte E, et al. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol 1998;11:1521-8
   PubMed Web of Science ®Google Scholar
• Eriksson T, Bjorkman S, Roth B, et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995;7:44-52
   PubMed Web of Science ®Google Scholar
• Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 2004;43:311-27
   PubMed Web of Science ®Google Scholar
• Faigle JW, Keberle H, Friess W. The metabolic fate of Thalidomide. Experientia 1962;18:389-97
   Google Scholar
• Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989;17:402-5
   PubMed Web of Science ®Google Scholar
• Figg WD, Raje S, Bauer KS, et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 1999;88:121-5
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Figg WD, Hahn B, et al. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1997;41:2797-9
   PubMed Web of Science ®Google Scholar
• Teo SK, Colburn WA, Thomas SD. Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol 1999;39:1162-8
   PubMed Web of Science ®Google Scholar
• Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57:365-76
   PubMed Web of Science ®Google Scholar
• Lutwak-Mann C, Schmid K, Keberle H. Thalidomide in rabbit semen. Nature 1967;214:1018-20
   PubMed Web of Science ®Google Scholar
• Scheffler MR, Colburn W, Kook KA, et al. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. Clin Pharmacol Ther 1999;65:483-90
   PubMed Web of Science ®Google Scholar
• Tsambaos D, Bolsen K, Georgiou S, et al. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene. Arch Dermatol Res 1994;286:347-9
   PubMed Web of Science ®Google Scholar
• Wiener H, Krivanek P, Tuisl E, et al. Induction of drug metabolism in the rat by taglutimide, a sedative-hypnotic glutarimide derivative. Eur J Drug Metab Pharmacokinet 1980;5:93-7
   PubMedGoogle Scholar
• Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-34
   PubMed Web of Science ®Google Scholar
• Schumacher H, Blake D, Gillette J. Thalidomide solutions. Science 1966;154:1362
   PubMed Web of Science ®Google Scholar
• Eriksson T, Hoglund P, Turesson I, et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 2003;55:1701-6
   PubMed Web of Science ®Google Scholar
• Somers GF. Pharmacological properties of thalidomide (alpha-phthalidomido glutarimide), a new sedative hypnotic drug. Br J Hematol 1960;15:111-6
   Web of Science ®Google Scholar
• Dunzendorfer S, Schratzberger P, Reinisch N, et al. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium. Naunyn Schmiedebergs Arch Pharmacol 1997;356:529-35
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
   PubMed Web of Science ®Google Scholar
• Eisen T, Boshoff C, Vaughan M. Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: a phase II study. Proc Am Soc Clin Oncol 1998;17:441a
   Google Scholar
• Figg WD, Bergan R, Brawley O, et al. Randomized, phase II study of thalidomide in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 1998;16:333a
   Google Scholar
• Long G, Vredenburgh J, Rizzieri DA, et al. Pilot trial of thalidomide post-autolgous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:181a
   Google Scholar
• Marx GM, Levi JA, Bell DR, et al. A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer. Proc Am Soc Clin Oncol 1999;18:454a
   Google Scholar
• Eisen T. Thalidomide in solid malignancies. J Clin Oncol 2002;20:2607-9
   PubMed Web of Science ®Google Scholar
• Hwu WJ. New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology (Williston Park) 2000;14:25-8
   PubMedGoogle Scholar
• Cohen MH. Thalidomide in the treatment of high-grade gliomas. J Clin Oncol 2000;18:3453
   PubMedGoogle Scholar
• Musto P. Thalidomide therapy in adult patients with myelodysplastic syndrome: a north central cancer treatment group Phase II trial. Cancer 2007;109:1211-2
   PubMed Web of Science ®Google Scholar
• Govindarajan R. Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston Park) 2002;16:23-6
   PubMedGoogle Scholar
• Molica S. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 2007;48:866-9
   PubMed Web of Science ®Google Scholar
• Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002;13:1029-35
   PubMed Web of Science ®Google Scholar
• Steins MB, Padro T, Bieker R, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002;99:834-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002;20:302-6
   PubMed Web of Science ®Google Scholar
• Wohl DA, Aweeka FT, Schmitz J, et al. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis 2002;185:1359-63
   PubMed Web of Science ®Google Scholar
• Huang F, Wei JC, Breban M. Thalidomide in ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S158-61
   Google Scholar
• Pigott A, Casson D. Thalidomide in Crohn disease. J Pediatr Gastroenterol Nutr 2005;40:236
   PubMed Web of Science ®Google Scholar
• Fu LM, Fu-Liu CS. Thalidomide and tuberculosis. Int J Tuberc Lung Dis 2002;6:569-72
   PubMed Web of Science ®Google Scholar
• Aweeka F, Trapnell C, Chernoff M, et al. Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. J Clin Pharmacol 2001;41:1091-7
   PubMed Web of Science ®Google Scholar
• Flowers ME, Martin PJ. Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease. Leuk Lymphoma 2003;44:1141-6
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol 2004;5:385-94
   PubMed Web of Science ®Google Scholar
• Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117:1271-7
   PubMed Web of Science ®Google Scholar
• Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-21
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14
   PubMed Web of Science ®Google Scholar
• Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994;55:77-92
   PubMed Web of Science ®Google Scholar
• Shannon EJ, Ejigu M, Haile-Mariam HS, et al. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev 1992;63:5-11
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004;5:318-24
   PubMedGoogle Scholar
• Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004;5:112-7
   PubMedGoogle Scholar
• Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006;76:273-7
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006;91:133-6
   PubMed Web of Science ®Google Scholar
• Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006;81:889-95
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;18:856-63
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005;129:763-70
   PubMed Web of Science ®Google Scholar
• Sidra G, Williams CD, Russell NH, et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006;91:862-3
   PubMed Web of Science ®Google Scholar
• Dingli D, Rajkumar SV, Nowakowski GS, et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica 2005;90:1650-4
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004;89:826-31
   PubMed Web of Science ®Google Scholar
• Hussein MA, McCoy J, Jakubowiak A, et al. SWOG 0204; phase 2 trial of thalidomide (T) + dexamethasone (D) induction followed by tandem autotransplant (TAT) and prednisone (P) + T maintenance for multiple myeloma (MM). Blood 2005;106:a341-2
   Google Scholar
• Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9
   PubMed Web of Science ®Google Scholar
• Vogel DT, Luger, et al. Thalidomide and dexamethasone induction therapy is associated with superior progression-free survival after autotransplant for myeloma. ASH Annual Meeting Abstracts; 2005;106:1171
   Google Scholar
• Rajkumar SV, Hussein MA, Catalano J, et al. A multicenter, randomized, double blind, placebo controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2006;24:426s
   Google Scholar
• Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Sonneveld P, Breitkreutz I, et al. HOVON 50/GMMG-HD3-trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. Blood 2005;106:128a
   Google Scholar
• Macro M, Divine M, Uzunhan Y, et al. Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed MM: a randomized trial. Blood 2006;108:22a
   Web of Science ®Google Scholar
• Ludwig H, Tothova, et al. Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma. ASH Annual Meeting Abstracts; 2007;110:529
   Google Scholar
• Waage A, Gimsing, et al. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. ASH Annual Meeting Abstracts; 2007;110:78
   Google Scholar
• Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323-41
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. ASCO Meeting Abstracts; 2006;24:1
   Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon, et al. Melphalan-Prednisone-Thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients > = 75 years with multiple myeloma compared with Melphalan-Prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. ASH Annual Meeting Abstracts; 2007;110:75
   Google Scholar
• Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75:897-901
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508-15
   PubMed Web of Science ®Google Scholar
• Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations. Drug Saf 1992;7:116-34
   PubMed Web of Science ®Google Scholar
• Naina HVK, Lacy, et al. Incidence and clinical course of peripheral neuropathy in patients receiving thalidomide for the treatment of multiple myeloma. ASH Annual Meeting Abstracts; 2005;106:3475
   Google Scholar
• Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507-14
   PubMed Web of Science ®Google Scholar
• Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006;95:924-30
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma [Record Supplied By Publisher]. Leukemia 2007 [epub ahead of print]
   PubMedGoogle Scholar
• Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004;18:2044-6
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 2000;343:972-3
   PubMed Web of Science ®Google Scholar
• Hall VC, El-Azhary RA, Bouwhuis S, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003;48:548-52
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007;21:1294-9
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006;108:2159-64
   PubMed Web of Science ®Google Scholar
• Stirling DI. The pharmacology of thalidomide. Semin Hematol 2000;37:5-14
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson PG, Anderson KC. Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs 2006;15:171-9
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist 2007;12:664-89
   PubMed Web of Science ®Google Scholar
• Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy Blood 2001;98:3846-48
   PubMed Web of Science ®Google Scholar
• Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004;15:134-8
   PubMed Web of Science ®Google Scholar
• Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007;18:1369-75
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Torjman L, Ben Romdhane N, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (< 61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005;36:193-8
   Google Scholar
• Padmanabhan S, Miller K, Musiel L, et al. Bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide is an active salvage regimen in patients with relapsed or refractory multiple myeloma: final results of a phase II trial. Haematologica 2006:91:277 (Abstract)
   Google Scholar
• Leoni F, Casini C, Breschi C, et al. Low dose bortezomib, dexamethasone, thalidomide plus liposomal doxorubicin in relapsed and refractory myeloma. Haematologica 2006;91:281 (Abstract)
   Google Scholar
• Hollmig K, Stover J, Talamo G, et al. Bortezomib (VelcadeTM) + AdriamycinTM + Thalidomide + Dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). ASH Annual Meeting Abstracts 2004;104:2399
   Google Scholar
• Zangari M, Barlogie B, Burns Michael J, et al. Velcade (V)-Thalidomide (T)-Dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of Phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T. ASH Annual Meeting Abstracts 2005;106:2552
   Google Scholar
• Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767-72
   PubMed Web of Science ®Google Scholar
• Badros A, Goloubeva O, Fenton R, et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma 2006;7:210-6
   PubMedGoogle Scholar
• Wang M, Delasalle K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. ASH Annual Meeting Abstracts 2005;106:784
   Google Scholar
• Teoh G, Tan D, Hwang W, et al. Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves complete remission rates in patients with relapsed/refractory multiple myeloma. ASCO Meeting Abstracts 2006;24:17537
   Google Scholar
• Barlogie B, Anaissie E, Bolejack V, et al. High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants. ASCO Meeting Abstracts 2006;24:7519
   Google Scholar
• Terpos E, Anagnostopoulos A, Heath D, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1a and angiogenic cytokines. ASH Annual Meeting Abstracts 2006;108:3541
   Google Scholar
• Giralt S, Thandi R, Qazilbash M, et al. Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy with thalidomide/dexamethasone (TD) with or without bortezomib (VTD). ASH Annual Meeting Abstracts 2007;110:948
   Google Scholar
• Jagannath S, Bensinger B, Vescio R, et al. A Phase II study of bortezomib (Velcade®), cylophosphamide (Cytoxan®), thalidomide (Thalomid®) and dexamethasone as first-line therapy for multiple myeloma. ASH Annual Meeting Abstracts 2007;110:188
   Google Scholar
• Cavo M, Patriarca F, Tacchetti P, et al. Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 2007;110:73
   Google Scholar
• Palumbo A, Ambrosini MT, Benevolo G, et al. Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial. ASH Annual Meeting Abstracts 2006;108:407
   Google Scholar